RxDoctor Payments DataLook up a doctor →

Rudolph Evonich, MD

Clinical Cardiac Electrophysiology · Green Bay, WINPI 1205909967

Payments from drug & device makers

$831,808in general payments, 2019–2025

Across 286 payments — averaging $2908.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$365K
  • Medtronic$264K
  • Medical Device Business Services, Inc.$130K
  • Atricure, Inc.$65K
  • Boehringer Ingelheim$5K
  • Biosense Webster, Inc.$1K
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$91212%
  • Food & beverage$6,56587%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$831,808 in reported general payments places this provider in the 95th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

See all clinical cardiac electrophysiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$189,643
Medicare patients
1,141
Services billed
2,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$337,486
XareltoRivaroxaban51$53,563
MultaqDronedarone Hcl29$37,928
EntrestoSacubitril/Valsartan18$29,080
JardianceEmpagliflozin26$23,027
Flecainide Acetate72$3,936
Metoprolol Succinate206$2,675
Diltiazem 24hr Er (Cd)Diltiazem Hcl106$2,317
Amiodarone Hcl172$2,297
Propafenone Hcl22$1,732
Nebivolol Hcl16$1,511
Dofetilide12$941
Losartan Potassium66$846
Spironolactone80$551
Potassium Chloride30$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$337,486323 claims
Johnson & JohnsonXarelto$35$53,56351 claims
Sanofi-aventis U.S. LLCMultaq$12$37,92829 claims
NovartisEntresto$157$29,08018 claims
Boehringer IngelheimJardiance$4,706$23,02726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

Other clinical cardiac electrophysiology in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →